Description overdue on 08.02.2013

The analogue somastatina . The active component acts lanreotide. The basic substance can inhibit the secretion of hormones TSH, growth hormone, the secretion of pancreatic and intestinal glands (vasoactive peptides, insulin, gastrin, glucagon, hydrochloric acid, digestive enzymes). The drug acts is longer compared to somastatinom. The drug has no antitumor effects. Somatulinom comes in the form of freeze-dried product. Slurry is injected intramuscularly. The drug has a long-acting form of influence.

Indications:

Drug Usage Somatulinom recommends prescribers in acromegaly, which is associated with impaired growth hormone after radiotherapy or surgery. The drug is prescribed for carcinoid tumors   (symptomatic treatment). The drug is used after surgery on the pancreas (prophylactic), and endocrine tumors in gastroenteropankreaticheskoy system (symptomatic treatment), with persistent diarrhea in patients with a diagnosis of "AIDS" in acute pancreatitis.

Contraindications:

Somatulinom does not apply in case of intolerance lanreotide, breastfeeding and child bearing.

Side effects, overdose:

The digestive tract: stearrhea , Flatulence, vomiting, nausea, appetite disorders, softening the stool, abdominal pain, long-term treatment may asymptomatic cholelithiasis . In intramuscular injection site can be painful, burning, itching, redness, swelling. Occasionally on the background of treatment with developing Somatulinom hyperglycemia   or changing glucose tolerance. In case of overdose treatment is carried posimptomnoe.

Mode of application:

The drug comes in the form of a freeze-dried product, from which the solution is being prepared. Somatulinom administered intramuscularly. Before the course of treatment there is a compulsory test to evaluate the injection response (dynamic observation of symptoms associated with carcinoid tumors, dynamic observation of changes in the secretion of growth hormone). When kartsionoidnyh tumors, acromegaly drug is administered 1 time per 14 days in a dose of 30 mg. In case of failure, which is estimated by the level of growth hormone, the patient's feelings and clinical symptoms (diarrhea, sensation of heat when carcinoid tumors) medication injected 1 time in 10 days.

Special instructions:

Use of the drug Somatulinom possible only in specialized institutions. In patients with diabetes, treatment is carried out under mandatory and permanent control of blood sugar levels. Patients with diabetes first type is recommended to reduce the dose insulin 25%, the subsequent correction mode may be used depending on the level of sugar in the blood. Each injection of lanreotide, after which the solution in the syringe is greater than provided in the Regulations, recorded in a special register. When carcinoid tumors of the digestive tract to the start of therapy after being eliminated intestinal obstruction   neoplasms. Before the course of treatment and every six months is a compulsory ultrasound gallbladder . During prolonged and severe steatorrhea   does not require the appointment of pancreatin. In severe kidney disease and renal requires dynamic monitoring of the functional state of these organs and systems.

Drug Interactions:

Clinically significant drug interactions Pharmaceutical Somatulinom with other medicines have been registered.